Literature DB >> 12829800

Repeated observation of breast tumor subtypes in independent gene expression data sets.

Therese Sorlie1, Robert Tibshirani, Joel Parker, Trevor Hastie, J S Marron, Andrew Nobel, Shibing Deng, Hilde Johnsen, Robert Pesich, Stephanie Geisler, Janos Demeter, Charles M Perou, Per E Lønning, Patrick O Brown, Anne-Lise Børresen-Dale, David Botstein.   

Abstract

Characteristic patterns of gene expression measured by DNA microarrays have been used to classify tumors into clinically relevant subgroups. In this study, we have refined the previously defined subtypes of breast tumors that could be distinguished by their distinct patterns of gene expression. A total of 115 malignant breast tumors were analyzed by hierarchical clustering based on patterns of expression of 534 "intrinsic" genes and shown to subdivide into one basal-like, one ERBB2-overexpressing, two luminal-like, and one normal breast tissue-like subgroup. The genes used for classification were selected based on their similar expression levels between pairs of consecutive samples taken from the same tumor separated by 15 weeks of neoadjuvant treatment. Similar cluster analyses of two published, independent data sets representing different patient cohorts from different laboratories, uncovered some of the same breast cancer subtypes. In the one data set that included information on time to development of distant metastasis, subtypes were associated with significant differences in this clinical feature. By including a group of tumors from BRCA1 carriers in the analysis, we found that this genotype predisposes to the basal tumor subtype. Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829800      PMCID: PMC166244          DOI: 10.1073/pnas.0932692100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  27 in total

1.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  Associations between gene expressions in breast cancer and patient survival.

Authors:  T-K Jenssen; W P Kuo; T Stokke; E Hovig
Journal:  Hum Genet       Date:  2002-08-23       Impact factor: 4.132

3.  Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.

Authors:  Matt van de Rijn; Charles M Perou; Rob Tibshirani; Phillippe Haas; Olli Kallioniemi; Juha Kononen; Joachim Torhorst; Guido Sauter; Markus Zuber; Ossi R Köchli; Frank Mross; Holger Dieterich; Rob Seitz; Doug Ross; David Botstein; Pat Brown
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

4.  SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data.

Authors:  Maximilian Diehn; Gavin Sherlock; Gail Binkley; Heng Jin; John C Matese; Tina Hernandez-Boussard; Christian A Rees; J Michael Cherry; David Botstein; Patrick O Brown; Ash A Alizadeh
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

5.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

6.  On the diagnosis and treatment of breast cancer.

Authors:  M S Fox
Journal:  JAMA       Date:  1979-02-02       Impact factor: 56.272

7.  Molecular characterisation of soft tissue tumours: a gene expression study.

Authors:  Torsten O Nielsen; Rob B West; Sabine C Linn; Orly Alter; Margaret A Knowling; John X O'Connell; Shirley Zhu; Mike Fero; Gavin Sherlock; Jonathan R Pollack; Patrick O Brown; David Botstein; Matt van de Rijn
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

8.  Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Authors:  S Geisler; P E Lønning; T Aas; H Johnsen; O Fluge; D F Haugen; J R Lillehaug; L A Akslen; A L Børresen-Dale
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

9.  Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.

Authors:  Sabina Signoretti; Lucia Di Marcotullio; Andrea Richardson; Sridhar Ramaswamy; Beth Isaac; Montserrat Rue; Franco Monti; Massimo Loda; Michele Pagano
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 10.  BRCA1: mechanisms of inactivation and implications for management of patients.

Authors:  Richard D Kennedy; Jennifer E Quinn; Patrick G Johnston; D Paul Harkin
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

View more
  1851 in total

1.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Authors:  Lisa A Carey; Hope S Rugo; P Kelly Marcom; Erica L Mayer; Francisco J Esteva; Cynthia X Ma; Minetta C Liu; Anna Maria Storniolo; Mothaffar F Rimawi; Andres Forero-Torres; Antonio C Wolff; Timothy J Hobday; Anastasia Ivanova; Wing-Keung Chiu; Madlyn Ferraro; Emily Burrows; Philip S Bernard; Katherine A Hoadley; Charles M Perou; Eric P Winer
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 2.  Histological types of breast cancer: how special are they?

Authors:  Britta Weigelt; Felipe C Geyer; Jorge S Reis-Filho
Journal:  Mol Oncol       Date:  2010-04-18       Impact factor: 6.603

3.  Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Authors:  Marco Colleoni; Bernard F Cole; Giuseppe Viale; Meredith M Regan; Karen N Price; Eugenio Maiorano; Mauro G Mastropasqua; Diana Crivellari; Richard D Gelber; Aron Goldhirsch; Alan S Coates; Barry A Gusterson
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

4.  Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models.

Authors:  Huiping Liu; Manishkumar R Patel; Jennifer A Prescher; Antonia Patsialou; Dalong Qian; Jiahui Lin; Susanna Wen; Ya-Fang Chang; Michael H Bachmann; Yohei Shimono; Piero Dalerba; Maddalena Adorno; Neethan Lobo; Janet Bueno; Frederick M Dirbas; Sumanta Goswami; George Somlo; John Condeelis; Christopher H Contag; Sanjiv Sam Gambhir; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

5.  Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.

Authors:  Jason I Herschkowitz; Wei Zhao; Mei Zhang; Jerry Usary; George Murrow; David Edwards; Jana Knezevic; Stephanie B Greene; David Darr; Melissa A Troester; Susan G Hilsenbeck; Daniel Medina; Charles M Perou; Jeffrey M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-01       Impact factor: 11.205

6.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

7.  Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

Authors:  Mevlude Inanc; Metin Ozkan; Halit Karaca; Veli Berk; Oktay Bozkurt; Ayse Ocak Duran; Ersin Ozaslan; Hulya Akgun; Fatos Tekelioglu; Ferhan Elmali
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

8.  Igf1r as a therapeutic target in a mouse model of basal-like breast cancer.

Authors:  Apostolos Klinakis; Matthias Szabolcs; Guoying Chen; Shouhong Xuan; Hanina Hibshoosh; Argiris Efstratiadis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

Review 9.  Population and target considerations for triple-negative breast cancer clinical trials.

Authors:  Terry Hyslop; Yvonne Michael; Tiffany Avery; Hallgeir Rui
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

10.  Alcohol consumption and risk of breast cancer by molecular subtype: Prospective analysis of the nurses' health study after 26 years of follow-up.

Authors:  Kelly A Hirko; Wendy Y Chen; Walter C Willett; Bernard A Rosner; Susan E Hankinson; Andrew H Beck; Rulla M Tamimi; A Heather Eliassen
Journal:  Int J Cancer       Date:  2015-10-05       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.